Key facts
- aceRNA Technologies’s last known valuation is $11.5M.
- It has raised $8.8M; the latest was Later Stage VC ($6.2M) in May 2024.
- Notable investors include Mitsubishi UFJ Capital, SMBC Venture Capital, Japan External Trade Organization, Intellectual Property Acceleration Program for Startups, UTokyo Innovation Platform Company — 11 tracked in total.
- Status: Privately Held (backing).
Investors
11+- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for aceRNA Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for aceRNA Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About aceRNA Technologies
Developer of a novel drug designed to provide one class of gene-regulatory elements that control. The company specializes in regenerative medicine through the discovery of novel miRNA functions, enabling biological companies to remove undifferentiated cells and other unnecessary cells that are at risk of cancer through the application of RNA switches.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2018
- Employees
- 12
- Website
- acernatec.com/
- Ownership
- Privately Held (backing)
aceRNA Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in aceRNA Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on aceRNA Technologies in its N-PORT filings yet. We sweep new filings monthly.